360 filings
Page 10 of 18
CT ORDER
w4t5 xyq9t6
20 Aug 18
Confidential treatment order
12:00am
8-K
mtuw tj04h
7 Aug 18
Miragen Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
4:06pm
D
3ljv5lxu
6 Aug 18
$5M in equity, sold $1M, 1 investor
4:34pm
8-K
raz87zz28 ffp
6 Aug 18
Entry into a Material Definitive Agreement
4:16pm
8-K
5b5lpush4a4qj
10 Jul 18
Miragen Therapeutics Announces Initiation of Phase 2 Clinical Trial OFMRG-201
7:15am
8-K
o09y9p mxtr4km
28 Jun 18
Submission of Matters to a Vote of Security Holders
4:17pm
8-K
5wfws0o5j 4rafg
4 Jun 18
Miragen Therapeutics to Present First Cobomarsen Phase 1 Clinical Trial Data
12:00am
CT ORDER
k6ofe5x
22 May 18
Confidential treatment order
12:46pm
DEFA14A
20a yahv8bey89gc
15 May 18
Additional proxy soliciting materials
12:00am
8-K
mg57058tn 8eq3
9 May 18
Miragen Therapeutics Reports First Quarter 2018 Financial Results and Provides
4:15pm
8-K
062p tu4p01kzsje6l9
8 May 18
Miragen Therapeutics Announces New Interim Data from Phase 1 Clinical Trial of Cobomarsen In Mycosis Fungoides
4:18pm
8-K
ag8n4
2 May 18
Other Events
4:18pm
8-K
yi1al3oxmmyka
27 Apr 18
Other Events
7:13am
8-K
5zb7l47 oog1a
6 Apr 18
Entry into a Material Definitive Agreement
12:00am
8-K/A
d5mn2skd
27 Mar 18
Departure of Directors or Certain Officers
12:00am
8-K
hesesv9vuxp
27 Mar 18
Miragen Announces Initiation of Phase 1 Clinical Trial OFMRG-110
12:00am